LX2761 |
| Catalog No.GC36498 |
LX2761 es un inhibidor quÍmicamente estable y potente contra el cotransportador de glucosa dependiente de sodio 1 (SGLT1) y SGLT2 in vitro con IC50 de 2,2 nM y 2,7 nM para hSGLT1 y hSGLT2, pero muestra una inhibiciÓn especÍfica de SGLT1 en el tracto gastrointestinal (GI) .
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1610954-97-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
LX2761 is chemically stable and potent inhibitor against sodium-dependent glucose cotransporter 1 (SGLT1) and SGLT2 in vitro with IC50s of 2.2 nM and 2.7nM for hSGLT1 and hSGLT2, but displays specific SGLT1 inhibition in the gastrointestinal (GI) tract[1]. IC50: 2.2 nM (hSGLT1), 2.7nM (hSGLT2)[1]
[1]. Goodwin NC, et al. Discovery of LX2761, a Sodium-Dependent Glucose Cotransporter 1 (SGLT1) Inhibitor Restrictedto the Intestinal Lumen, for the Treatment of Diabetes. J Med Chem. 2017 Jan 26;60(2):710-721.
Average Rating: 5 (Based on Reviews and 27 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *